Check this video on what we do.
Mabswitch is developing ligand-programmable antibody therapeutics designed to provide dynamic control over biological activity after administration. The company is applying its programmable antibody platforms to next-generation oncology therapeutics with the goal of expanding therapeutic windows and enabling new approaches to drug design. MabSwitch is advancing a multi-product, multi-modality clinical pipeline with a focus on developing First and/or Best in class next-generation antibody therapeutic candidates.
We liberate therapeutic antibodies from the usual constraints of a fixed functional profile. Switches can improve safety of bi- or multispecific antibodies with longer plasma half life.
We are developing switchable affinity T-cell engagers (SaefTE) and antibody drug conjugates (SaefADC), to provide temporal and spatial control over target engagement in the patient.
Matching CAR-T cell activity in-vivo with tumor loads or controlling inflammatory side effects is only the start. Adding an affinity switch to silence or boost long half-life drug function in real time in the patient allows re-thinking of many therapeutic concepts.
Download poster presented at Festival of Biologics, San Diego, April 2024